Form 4: Tyra Biosciences COO Granted 300,000 Stock Options

Tyra Biosciences' Chief Operating Officer, Bhavesh Ashar, was granted 300,000 stock options with an exercise price of $20.81, vesting over four years.

Summary

• Bhavesh Ashar, Chief Operating Officer of Tyra Biosciences, Inc. (TYRA), was granted 300,000 stock options.
• The transaction date for this grant was December 1, 2025.
• Each stock option has an exercise price of $20.81.
• The options will vest over a four-year period: 25% of the shares subject to the option will vest on December 1, 2026, and 1/48th of the total number of shares will vest monthly thereafter.
• Vesting is contingent upon Mr. Ashar's continuous service to the Issuer through each vesting date.
• The expiration date for these stock options is November 30, 2035.

Sentiment

Score: 6

Explanation: The filing indicates a standard executive compensation event, which is generally a neutral to slightly positive signal as it aligns management's interests with long-term company performance, without revealing new operational or financial performance data.

Positives

• The grant of 300,000 stock options to the Chief Operating Officer aligns executive incentives with long-term shareholder value creation.
• The vesting schedule encourages continuous service and commitment from a key executive over a multi-year period.

Future Outlook

The vesting schedule for the stock options, extending through December 1, 2026, and monthly thereafter, indicates an expectation of the Chief Operating Officer's continued service to the company for the foreseeable future.

Industry Context

The granting of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of long-term incentive compensation to attract, retain, and motivate talent, aligning their interests with shareholder returns.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common executive compensation structure in the biotech sector, similar to practices observed at comparable growth-stage biopharmaceutical companies.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Corporate Governance

Related Party Transactions

• Grant of 300,000 stock options to Bhavesh Ashar, the Chief Operating Officer, which is a standard compensation transaction between the company and an executive officer.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Operating Officer's financial incentives with the company's stock performance, potentially benefiting long-term shareholder value.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies.

Next Steps

• Continued service of the Chief Operating Officer to meet vesting conditions.
• Monthly vesting of stock options following the initial 25% vesting on December 1, 2026.

Key Dates

Keywords

Tyra Biosciences, TYRA, Stock Option, Executive Compensation, Form 4, Bhavesh Ashar, COO, Insider Transaction